You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension

Julius, Stevoa; Egan, Brent M.b; Kaciroti, Niko A.c; Nesbitt, Shawna D.d; Chen, Andrew K.e; for TROPHY investigators

Journal of Hypertension:
doi: 10.1097/HJH.0000000000000032
ORIGINAL PAPERS: Epidemiology
Abstract

Background: Previous studies reported increased white blood cell counts (WBCCs), an inflammatory marker, in hypertension, prehypertension and metabolic syndrome. Evidence suggests that inflammation precedes blood pressure (BP) elevation and may contribute to incident hypertension. Angiotensin receptor blockers (ARBs) may reduce inflammation. We analyzed WBCC trends in TRial Of Preventing HYpertension (TROPHY) to determine if this inflammatory marker predicted incident hypertension in prehypertensive individuals and whether randomized assignment to the ARB candesartan (391 individuals) for 2 years, lowered WBCC compared with placebo-treated controls (381 individuals).

Methods: A new analysis of TROPHY trial data.

Results: In the total population, baseline BMI correlated with WBCC (r = 0.185, P < 0.0001), neutrophils (r = 0.135, P < 0.001) and lymphocytes (r = 0.204, P < 0.0001). Baseline triglycerides also correlated significantly with inflammatory markers. Despite a wide range of home BP (HBP) values, HBP did not correlate with baseline WBCC counts. After 2 years, candesartan decreased placebo corrected HBP by –5.5/–2.5 mmHg, (P < 0.0001), but WBCC, neutrophil and lymphocyte counts were not different in placebo and in candesartan groups. Baseline WBCC, neutrophils and lymphocyte counts did not predict incident hypertension in the placebo group.

Conclusion: In TROPHY, candesartan lowered BP but did not alter WBCC. Baseline WBCC did not predict incident hypertension. Our findings do not support the hypothesis that inflammation contributes to incident hypertension or that ARB treatment suppresses inflammation. The significant independent association of WBCC with baseline BMI and triglycerides is consistent with the evidence that obesity and insulin resistance are associated with inflammation. The findings highlight the importance of effective lifestyle modification in prehypertension to reduce inflammatory cardio-metabolic risk and suppress transition to hypertension.

Author Information

aDivision of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan

bDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina

cCenter for Human Growth and Development, University of Michigan, Ann Arbor, Michigan

dDepartmentof Internal Medicine, University of Texas Southwestern, Dallas, Texas

eDivision of Cardiovascular Disease, Scripps Clinic, La Jolla, California, USA

Correspondence to Stevo Julius, MD, ScD, University of Michigan, Division of Cardiovascular Medicine, 2368 Cardiovascular Center SPC 5853, 1500 E. Medical Center Dr Ann Arbor, MI 48109, USA. Tel: +1 734 998 7955; fax: +1 734; 998 8018; e-mail: sjulius@umich.edu

Abbreviations: ARB, angiotensin receptor blockers; BMI, body mass index; BP, blood pressure; CRP, C reactive protein; CV, cardiovascular; HBP, home blood pressure; hsCRP, high sensitivity CRP; LOCF, last observation carried forward; RAS, renin–angiotensin system; WBCC, white blood cell counts

Received 2 August, 2013

Revised 30 September, 2013

Accepted 30 September, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins